Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research/analytical instrumentation and reagent sectors.
Series C generates €71mm for Biocartis
Four-year-old Swiss molecular diagnostics company Biocartis NV has raised €71mm ($96mm) in its Series C financing led by Biocartis'...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Pfizer and Arvinas have agreed to out-license their PROTAC breast cancer candidate, vepdegestrant, with Arvinas cutting jobs and refocusing on early-stage assets.
Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!
Plus deals involving Adagene/Exelixis, Biocytogen/Tubulis, Kwangdong/Ocugen, Dr. Reddy’s/J&J, Zydus/Synthon, Stallergenes/Nuance, Argo/Novartis, XW Pharma/Avadel, Biocytogen/Merck & Co., JCR/Medipal, Novatim/Radiance and more.
Deal Snapshot: CSL secures exclusive option to acquire VarmX, depending on results for a Phase III trial for its lead compound, VMX-C001, a reversal agent for Factor Xa inhibitors.
The start-up, which spent two years operating in stealth mode, has a clinical-stage anti-VEGF/Ang2 drug to rival Roche’s Vabysmo, and is on the hunt for additional ophthalmology assets.
Takeda's APAC chief talks about driving affordability and access for products like Adcetris and Qdenga, focusing on the region's diverse needs. “Watch this space” he said on the Japanese group’s Innovation Capability Centers, as they shape digital solutions to transform operations.
The UK-headquartered company is investing heavily in the US, with CEO Emma Walmsley among business leaders greeting President Trump on his state visit to the country.
